Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large.
Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
Archive for the ‘Agency Insight’ Category
Putting the M Back in M&A
December 13th, 2011 
Jennifer Ringler 
Posted in Agency Insight, BIOCOM, Blog, Companies, Deals, Diagnostics, FDA, Funding, Joe Panetta, M&A, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, venture capital, Videos 
Tags: biotech, biotech food social media 
Comments OffThe HCR Taxman Cometh
September 13th, 2011 Guest Blogger By Tom Norton
As the country struggles with the current economic malaise, and the pharmaceutical industry enters into yet another difficult quarter of “trying to make the numbers,” one matter that I doubt many Rx execs are thinking about today is the HCR Taxman. That’s too bad. They probably should. That’s because he’s coming for the [...]
Posted in Advertising, Agency Insight, Blog, Companies, compliance, Corporate Responsibility, Diagnostics, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Strategy, Universities, Videos Tags: biotech Comments OffBiosimilars Spend to Reach $2.5 Bln by 2015: IMS
May 17th, 2011 Ben Comer Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion.
On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, [...]
Posted in Agency Insight, biosimilars, Blog, Companies, Diagnostics, Emerging Markets, Europe, forecast, Funding, IMS Health, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Strategy, Universities, Videos Tags: biotech Comments Off